Drugs / OCV-501
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01475370 | Jan 2012 → Dec 2016 | acute myeloid leukemia | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01440920 | Sep 2011 → Mar 2013 | acute myeloid leukemia | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01961882 | Oct 2013 → Nov 2017 | acute myeloid leukemia | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCV-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01961882 ↗ |
| Route | Subcutaneous | “subcutaneously administered once a week, 4 times at the dose of 0.3 mg” NCT01440920 ↗ |